Yuan Zhi
Stock Analyst at B. Riley Securities
(4.49)
# 1,106
Out of 5,004 analysts
138
Total ratings
40.9%
Success rate
19.1%
Average return
Main Sectors:
Stocks Rated by Yuan Zhi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PGEN Precigen | Initiated Coverage: Buy | $12 | $7.75 | +54.84% | 1 | Sep 25, 2026 | |
| LYEL Lyell Immunopharma | Reiterated: Buy | $44 | $9.85 | +346.70% | 2 | Sep 24, 2026 | |
| NUTX Nutex Health | Reiterated: Buy | $325 | $220.11 | +47.65% | 1 | Sep 4, 2026 | |
| LNTH Lantheus Holdings | Downgraded: Hold | $129 → $105 | $99.74 | +5.67% | 28 | Aug 18, 2026 | |
| HYPR Hyperfine | Reiterated: Buy | $2 → $1.6 | $0.8133 | +96.73% | 9 | Aug 10, 2026 | |
| STLN Starling Oncology | Reiterated: Buy | $6 → $11 | $6.66 | +65.17% | 3 | Aug 7, 2026 | |
| MIR Mirion Technologies | Reiterated: Buy | $29 | $15.59 | +86.02% | 11 | Jul 30, 2026 | |
| WHWK Whitehawk Therapeutics | Initiated Coverage: Buy | $10 | $3.74 | +167.38% | 1 | Jun 25, 2026 | |
| TNGX Tango Therapeutics | Rated: Buy | $21 → $35 | $24.92 | +40.45% | 7 | Jun 9, 2026 | |
| RDNT RadNet | Rated: Buy | $87 → $83 | $70.79 | +17.25% | 6 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $5.33 | +50.09% | 1 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $11 → $13 | $2.52 | +415.87% | 13 | Mar 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $3.50 | +185.71% | 2 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 → $16 | $1.65 | +869.70% | 6 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 → $3 | $4.38 | n/a | 3 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $16 → $2 | $1.20 | n/a | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $19 → $15 | $17.41 | n/a | 14 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $79 | $34.02 | n/a | 12 | Feb 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $38.49 | n/a | 5 | Jan 9, 2023 |
Precigen
Sep 25, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $7.75
Upside: +54.84%
Lyell Immunopharma
Sep 24, 2026
Reiterated: Buy
Price Target: $44
Current: $9.85
Upside: +346.70%
Nutex Health
Sep 4, 2026
Reiterated: Buy
Price Target: $325
Current: $220.11
Upside: +47.65%
Lantheus Holdings
Aug 18, 2026
Downgraded: Hold
Price Target: $129 → $105
Current: $99.74
Upside: +5.67%
Hyperfine
Aug 10, 2026
Reiterated: Buy
Price Target: $2 → $1.6
Current: $0.8133
Upside: +96.73%
Starling Oncology
Aug 7, 2026
Reiterated: Buy
Price Target: $6 → $11
Current: $6.66
Upside: +65.17%
Mirion Technologies
Jul 30, 2026
Reiterated: Buy
Price Target: $29
Current: $15.59
Upside: +86.02%
Whitehawk Therapeutics
Jun 25, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $3.74
Upside: +167.38%
Tango Therapeutics
Jun 9, 2026
Rated: Buy
Price Target: $21 → $35
Current: $24.92
Upside: +40.45%
RadNet
May 1, 2026
Rated: Buy
Price Target: $87 → $83
Current: $70.79
Upside: +17.25%
Mar 25, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $5.33
Upside: +50.09%
Mar 18, 2026
Rated: Buy
Price Target: $11 → $13
Current: $2.52
Upside: +415.87%
Dec 17, 2025
Reiterated: Buy
Price Target: $10
Current: $3.50
Upside: +185.71%
Dec 16, 2025
Reiterated: Buy
Price Target: $13 → $16
Current: $1.65
Upside: +869.70%
Oct 2, 2024
Reiterated: Buy
Price Target: $4 → $3
Current: $4.38
Upside: n/a
Aug 7, 2024
Downgraded: Hold
Price Target: $16 → $2
Current: $1.20
Upside: n/a
Jul 30, 2024
Upgraded: Buy
Price Target: $19 → $15
Current: $17.41
Upside: n/a
Feb 7, 2024
Reiterated: Buy
Price Target: $79
Current: $34.02
Upside: n/a
Jan 9, 2023
Reiterated: Buy
Price Target: $34
Current: $38.49
Upside: n/a